Inflammagen's Shok-Pak Taking on Septic Stock in Phase II Trial
If early human trial results from Inflammagen Therapeutics Inc. are borne out in its new Phase II pilot study, disclosed Monday, the company could have a major blockbuster on its hands, according to CEO John Rodenrys.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST